A Phase III Study to Efficacy and Safety of DWC202405/DWC202313 and DWC202314 in Patients With Hypertension

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 198 participants.

Also called NCT06671392

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 198 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT06671392
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT06671392. Randomized; double masking; primary purpose treatment. Start 2025-02-24 (actual); primary completion 2026-02-05 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Phase III Study to Efficacy and Safety of DWC202405/DWC202313 and DWC202314 in Patients With Hypertension
Condition
Essential Hypertension
Intervention (Drug)
DWC202405
Intervention (Drug)
DWC202405, DWC202314
Intervention (Drug)
DWC202405, DWC202314P
Intervention (Drug)
DWC202313, DWC202314
Intervention (Drug)
DWC202313, DWC202314P
Lead sponsor
Daewoong Pharmaceutical Co. LTD. (class: industry)

Record details

Record id
cardio:ct-nct06671392
Content hash
f50009ee05cbe1a1dbe6936561845f55526890757996c9e781cd848e841fe6b7